Literature DB >> 3327682

Pharmacodynamic properties of felodipine.

B Ljung1, M Nordlander.   

Abstract

This overview presents the pharmacodynamic properties of felodipine as studied in animal experiments with emphasis on results from our laboratory. Felodipine is 100-fold more potent in causing inhibition of spontaneously active vascular smooth muscle than myocardium in vitro. This vascular selectivity is significantly greater than that of nifedipine (potency ratio 15). Verapamil, D-600, La3+ and reduction of [Ca2+]o lack selectivity. The cellular mechanisms underlying this variable selectivity are not clear at present. In conscious spontaneously hypertensive rats (SHR), the plasma concentration required for 20% reduction of mean arterial pressure is approximately 10 nmol. Mean arterial pressure is lowered dose-dependently as a result of reduced peripheral vascular resistance accompanied by increased cardiac output due to transient tachycardia and increased stroke volume. There was rapid resetting of the baroreflex set point but unaltered sensitivity after felodipine and hydralazine in SHR. Therefore, the reflexogenic increase in heart rate and plasma renin activity subsided within 3 to 5 hours of continuous felodipine administration in SHR. In addition, there was a uniform dilatation of the peripheral vascular beds after felodipine administration. During long term treatment of SHR with felodipine, progression of left ventricular and vascular wall hypertrophy was prevented. Within the 'therapeutic dose range', the only primary effect observed in addition to arterial vasodilation is diuresis/natriuresis caused by a renal tubular action.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3327682     DOI: 10.2165/00003495-198700343-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  23 in total

1.  Felodipine sensitivity in vivo and in vitro of activation pathways in vascular smooth muscles.

Authors:  B Ljung; M Nordlander; B Johansson
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

Review 2.  Vascular smooth muscle. II. Pharmacology of normal and hypotensive vessels.

Authors:  A P Somlyo; A V Somlyo
Journal:  Pharmacol Rev       Date:  1970-06       Impact factor: 25.468

3.  Adrenergic excitatory influences on initiation and conduction of electrical activity in the rat portal vein.

Authors:  B Ljung; L Stage
Journal:  Acta Physiol Scand       Date:  1970-09

4.  Haemodynamic effects of short and long term administration of felodipine in spontaneously hypertensive rats.

Authors:  M Nordlander
Journal:  Drugs       Date:  1985       Impact factor: 9.546

5.  Baroreflex control of renin release in spontaneously hypertensive rats after administration of felodipine.

Authors:  M Nordlander; R Horton; P Thalén
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Electrical and mechanical characteristics of vascular smooth muscle response to norepinephrine and isoproterenol.

Authors:  B Johansson; O Johsson; J Axelsson; B Wahlström
Journal:  Circ Res       Date:  1967-11       Impact factor: 17.367

7.  Vascular selectivity of felodipine.

Authors:  B Ljung
Journal:  Drugs       Date:  1985       Impact factor: 9.546

8.  Effects of felodipine on renal function in animals.

Authors:  G F DiBona
Journal:  Drugs       Date:  1985       Impact factor: 9.546

9.  Effects of felodipine on resistance and capacitance vessels in patients with essential hypertension.

Authors:  A L Muir; C G Wathen; W J Hannan
Journal:  Drugs       Date:  1985       Impact factor: 9.546

10.  Effect of felodipine on renal hemodynamics and excretion in the dog.

Authors:  B Ek; M Sjölander; G F DiBona; M Hallbäck-Nordlander; B Ljung
Journal:  Proc Soc Exp Biol Med       Date:  1985-06
View more
  2 in total

1.  The effects of Ca2+ antagonists and hydralazine on central 5-hydroxytryptamine biochemistry and function in rats and mice.

Authors:  A R Green; R J DeSouza; E M Davies; A J Cross
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

2.  Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group.

Authors:  W A Littler; D J Sheridan
Journal:  Br Heart J       Date:  1995-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.